Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02121613 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT02121613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02121613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2014
Completion date
June 30, 2016
Enrollment
833 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia (bph)